Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Preceptorship on Lung Cancer 2024: Paris

15 - 16 Nov 2024

Paris, France

ESMO-Preceptorship-Lung-Cancer-1000x1000

Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.

The copyright protected educational resources from this event are for personal usage only and not to be shared with any third parties.

Learning objectives

  • To learn about best clinical practice in the management of NSCLC in early, locally advanced, and metastatic stages
  • To learn about the management of patients with actionable driver alterations and novel targeted agents for advanced NSCLC
  • To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
  • To learn about the systemic treatment of mesothelioma, SCLC and thymoma

This event has been supported by an unrestricted educational grant from AstraZeneca and BeiGene.

Hide
Filter by:

There are 29 resources available

Welcome and Introduction

Presenter: S. Peters, CH, D. Planchard, FR

Session: Welcome and Introduction

Resources:

Slides

Webcast

Immunotherapy for AGA in NSCLC

Presenter: F. Barlesi, FR

Session: Session 2 – Immuno-Oncology Treatment Paradigms in Advanced NSCLC

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.